2 Matching Annotations
  1. Dec 2020
  2. investors.modernatx.com investors.modernatx.com
    Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc.
    1
    1. marta_radosevic 01 Dec 2020

      Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc. (n.d.). Retrieved 1 December 2020, from https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy/

      is:webpage lang:en COVID-19 Moderna vaccine phase 3 study vaccine efficacy analysis patient safety biotechnology
    Visit annotations in context

    Tags

    Annotators

    URL

    investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy/
  3. Nov 2018
  4. www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
    PEDS20133885 94..101
    1
    1. mattwramotar 11 Nov 2018
      Experts suggest family engagement in care can improve safety for hospitalizedchildren

      Connection between family engagement in care and safety

      family engagement patient safety
    Visit annotations in context

    Tags

    Annotators

    URL

    ncbi.nlm.nih.gov/pmc/articles/PMC4279061/pdf/peds.2013-3885.pdf